［1］ HUANG H,WENG H,CHEN J.M(6)A modification in coding and non-coding RNAs:roles and therapeutic implications in cancer［J］.Cancer Cell,2020,37(3):270-288.
［2］ LI F,ZHAO D,WU J,et al.Structure of the YTH domain of human YTHDF2 in complex with an m(6)A mononucleotide reveals an aromatic cage for m(6)A recognition［J］.Cell Res,2014,24(12):1490-1492.
［3］ ROIGNANT JY,SOLLER M.M(6)A in mRNA:an ancient mechanism for fine-tuning gene expression［J］.Trends Genet,2017,33(6):380-390.
［4］ PAN Y,MA P,LIU Y,et al.Multiple functions of m(6)A RNA methylation in cancer［J］.J Hematol Oncol,2018,11(1):48.
［5］ DOMINISSINI D,MOSHITCH-MOSHKOVITZ S,SCHWARTZ S,et al.Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq［J］.Nature,2012,485(7397):201-206.
［6］ WANG Y,LI Y,TOTH JI,et al.N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells［J］.Nat Cell Biol,2014,16(2):191-198.
［7］ MEYER KD,JAFFREY SR.Rethinking m(6)A readers,writers,and erasers［J］.Annu Rev Cell Dev Biol,2017,33:319-342.
［8］ DU H,ZHAO Y,HE J,et al.YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex［J］.Nat Commun,2016,7:12626.
［9］ PARIS J,MORGAN M,CAMPOS J,et al.Targeting the RNA m(6)A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia［J］.Cell Stem Cell,2019,25(1):137-148.
［10］ CHEN Z,SHAO YL,WANG LL,et al.YTHDF2 is a potential target of AML1/ETO-HIF1alpha loop-mediated cell proliferation in t(8;21) AML［J］.Oncogene,2021,40(22):3786-3798.
［11］ ZACCARA S,RIES RJ,JAFFREY SR.Reading,writing and erasing mRNA methylation［J］.Nat Rev Mol Cell Biol,2019,20(10):608-624.
［12］ HARTMANN AM,NAYLER O,SCHWAIGER FW,et al.The interaction and colocalization of Sam68 with the splicing-associated factor YT521-B in nuclear dots is regulated by the Src family kinase p59(fyn)［J］.Mol Biol Cell,1999,10(11):3909-3926.
［13］ WANG X,LU Z,GOMEZ A,et al.N6-methyladenosine-dependent regulation of messenger RNA stability［J］.Nature,2014,505(7481):117-120.
［14］ WOJTAS MN,PANDEY RR,MENDEL M,et al.Regulation of m(6)A transcripts by the 3'-->5' RNA helicase YTHDC2 is essential for a successful meiotic program in the mammalian germline［J］.Mol Cell,2017,68(2):374-387.
［15］ DHOTE V,SWEENEY TR,KIM N,et al.Roles of individual domains in the function of DHX29,an essential factor required for translation of structured mammalian mRNAs［J］.Proc Natl Acad Sci USA,2012,109(46):3150-3159.
［16］ WANG X,ZHAO BS,ROUNDTREE IA,et al.N(6)-methyladenosine modulates messenger RNA translation efficiency［J］.Cell,2015,161(6):1388-1399.
［17］ CARDELLI M,MARCHEGIANI F,CAVALLONE L,et al.A polymorphism of the YTHDF2 gene (1p35) located in an Alu-rich genomic domain is associated with human longevity［J］.J Gerontol A Biol Sci Med Sci,2006,61(6):547-556.
［18］ WANG JY,LU AQ.The biological function of m6A reader YTHDF2 and its role in human disease［J］.Cancer Cell Int,2021,21(1):109.
［19］ XU P,HU K,ZHANG P,et al.Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis［J］.Cancer Cell Int,2022,22(1):13.
［20］ ZHANG C,HUANG S,ZHUANG H,et al.YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation［J］.Oncogene,2020,39(23):4507-4518.
［21］ HOU J,ZHANG H,LIU J,et al.YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma［J］.Mol Cancer,2019,18(1):163.
［22］ XU F,LI J,NI M,et al.FBW7 suppresses ovarian cancer development by targeting the N(6)-methyladenosine binding protein YTHDF2［J］.Mol Cancer,2021,20(1):45.
［23］ SHENG H,LI Z,SU S,et al.YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation［J］.Carcinogenesis,2020,41(5):541-550.
［24］ LI Y,SHENG H,MA F,et al.RNA m(6)A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/beta-catenin signaling［J］.Cell Death Dis,2021,12(5):479.
［25］ ZHAO T,WANG M,ZHAO X,et al.YTHDF2 inhibits the migration and invasion of lung adenocarcinoma by negatively regulating the FAM83D-TGFbeta1-SMAD2/3 pathway［J］.Front Oncol,2022,12:763341.
［26］ EINSTEIN JM,PERELIS M,CHAIM IA,et al.Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer［J］.Mol Cell,2021,81(15):3048-3064.
［27］ ZHONG L,LIAO D,ZHANG M,et al.YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma［J］.Cancer Lett,2019,442:252-261.
［28］ 张杰,皮静楠,刘越,等.敲低MGC-803胃癌细胞YTHDF2抑制其增殖并促进其凋亡［J］.细胞与分子免疫学杂志,2017,33(12):1628-1634.
ZHANG J,PI JN,LIU Y,et al.Knockdown of YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) inhibits proliferation and promotes apoptosis in MGC-803 gastric cancer cells［J］.Chin J Cell Mol Imm,2017,33(12):1628-1634.
［29］ SHEN X,ZHAO K,XU L,et al.YTHDF2 inhibits gastric cancer cell growth by regulating FOXC2 signaling pathway［J］.Front Genet,2020,11:592042.
［30］ LI H,ZHANG N,JIAO X,et al.Downregulation of microRNA-6125 promotes colorectal cancer growth through YTHDF2-dependent recognition of N6-methyladenosine-modified GSK3beta［J］.Clin Transl Med,2021,11(10):e602.
［31］ CHEN J,SUN Y,XU X,et al.YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells［J］.Cell Cycle,2017,16(23):2259-2271.
［32］ TAN Z,SHI S,XU J,et al.RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m(6)A-YTHDF2-dependent manner［J］.Oncogene,2022,41(20):2860-2872.
［33］ XIE H,LI J,YING Y,et al.METTL3/YTHDF2 m(6) A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer［J］.J Cell Mol Med,2020,24(7):4092-4104.
［34］ LI J,XIE H,YING Y,et al.YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer［J］.Mol Cancer,2020,19(1):152.
［35］ DU C,LV C,FENG Y,et al.Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression［J］.J Exp Clin Cancer Res,2020,39(1):223.
［36］ HONG L,PU X,GAN H,et al.YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m(6)A［J］.J Cancer,2021,12(13):3809-3818.
［37］ DIXIT D,PRAGER BC,GIMPLE RC,et al.The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells［J］.Cancer Discov,2021,11(2):480-499.
［38］ FANG R,CHEN X,ZHANG S,et al.EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma［J］.Nat Commun,2021,12(1):177.
［39］ CHAI RC,CHANG YZ,CHANG X,et al.YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m(6)A modification to activate NF-kappaB and promote the malignant progression of glioma［J］.J Hematol Oncol,2021,14(1):109.
［40］ 刁新峰,李新茂,候亮,等.YTHDF2通过诱导IGFBP7的mRNA衰变激活PI3K/AKT信号转导通路促进胶质母细胞瘤进展的研究［J］.中国癌症杂志,2022,32(03):218-227.
DIAO XF,LI XM,HOU L,et al.YTHDF2 promotes progression of glioblastoma via inducing mRNA decay of IGFBP7 and activating PI3K/AKT signaling pathway［J］.China Oncology,2022,32(03):218-227.
［41］ YU J,CHAI P,XIE M,et al.Histone lactylation drives oncogenesis by facilitating m(6)A reader protein YTHDF2 expression in ocular melanoma［J］.Genome Biol,2021,22(1):85.
［42］ HUA Z,WEI R,GUO M,et al.YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis［J］.Oncogene,2022,41(10):1482-1491.
［43］ WHITTAKER S,MARAIS R,ZHU AX.The role of signaling pathways in the development and treatment of hepatocellular carcinoma［J］.Oncogene,2010,29(36):4989-5005.
［44］ KOMPOSCH K,SIBILIA M.EGFR signaling in liver diseases［J］.Int J Mol Sci,2015,17(1):30.
［45］ NEUZILLET C,TIJERAS-RABALLAND A,DE MESTIER L,et al.MEK in cancer and cancer therapy［J］.Pharmacol Ther,2014,141(2):160-171.
［46］ SUN L,CHEN X,JIN X,et al.Identification and characterization of human MIBP1 gene in glioma cell differentiation［J］.J Mol Neurosci,2014,52(2):294-301.
［47］ YUAN JH,YANG F,WANG F,et al.A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma［J］.Cancer Cell,2014,25(5):666-681.
［48］ BOLLRATH J,PHESSE TJ,VON BURSTIN VA,et al.Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis［J］.Cancer Cell,2009,15(2):91-102.
［49］ PIZZINGA M,HARVEY RF,RUBIO A,et al.Don't shoot the messenger...shoot the reader［J］.Mol Cell,2021,81(15):3041-3042.
［50］ THIERY JP,ACLOQUE H,HUANG RY,et al.Epithelial-mesenchymal transitions in development and disease［J］.Cell,2009,139(5):871-890.
［51］ LAMOUILLE S,XU J,DERYNCK R.Molecular mechanisms of epithelial-mesenchymal transition［J］.Nat Rev Mol Cell Biol,2014,15(3):178-196.
［52］ WANG J,XIANG H,LU Y,et al.Role and clinical significance of TGFbeta1 and TGFbetaR1 in malignant tumors (review)［J］.Int J Mol Med,2021,47(4):55.
［53］ MITTAL V.Epithelial mesenchymal transition in tumor metastasis［J］.Annu Rev Pathol,2018,13:395-412.
［54］ GOEL S,WONG AH,JAIN RK.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease［J］.Cold Spring Harb Perspect Med,2012,2(3):a006486.
［55］ WAGENBLAST E,SOTO M,GUTIERREZ-ANGEL S,et al.A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis［J］.Nature,2015,520(7547):358-362.
［56］ RANKIN EB,GIACCIA AJ.Hypoxic control of metastasis［J］.Science,2016,352(6282):175-180.
［57］ VALIENTE M,OBENAUF AC,JIN X,et al.Serpins promote cancer cell survival and vascular co-option in brain metastasis［J］.Cell,2014,156(5):1002-1016.
［58］ YAMINI B.NF-kappaB,mesenchymal differentiation and glioblastoma［J］.Cells,2018,7(9):125.
［59］ PLAKS V,KONG N,WERB Z.The cancer stem cell niche:how essential is the niche in regulating stemness of tumor cells［J］.Cell Stem Cell,2015,16(3):225-238.
［60］ LI Z,QIAN P,SHAO W,et al.Suppression of m(6)A reader Ythdf2 promotes hematopoietic stem cell expansion［J］.Cell Res,2018,28(9):904-917.
［61］ WANG H,ZUO H,LIU J,et al.Loss of YTHDF2-mediated m(6)A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration［J］.Cell Res,2018,28(10):1035-1038.
［62］ MARTINEZ-REYES I,CHANDEL NS.Cancer metabolism:looking forward［J］.Nat Rev Cancer,2021,21(10):669-680.
［63］ HANAHAN D,WEINBERG RA.Hallmarks of cancer:the next generation［J］.Cell,2011,144(5):646-674.
［64］ ZHANG D,TANG Z,HUANG H,et al.Metabolic regulation of gene expression by histone lactylation［J］.Nature,2019,574(7779):575-580.
［65］ SARFRAZ I,RASUL A,HUSSAIN G,et al.6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells:from cancer initiation to metastasis and chemoresistance［J］.Biofactors,2020,46(4):550-562.
［66］ WOOD T.Physiological functions of the pentose phosphate pathway［J］.Cell Biochem Funct,1986,4(4):241-247.
［67］ LIN R,ELF S,SHAN C,et al.6-Phosphogluconate dehydrogenase links oxidative PPP,lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling［J］.Nat Cell Biol,2015,17(11):1484-1496.
［68］ ZHENG W,FENG Q,LIU J,et al.Inhibition of 6-phosphogluconate dehydrogenase reverses cisplatin resistance in ovarian and lung cancer［J］.Front Pharmacol,2017,8:421.
［69］ 张梦雅,孙艳娣,骆严.磷酸戊糖途径重编程与肿瘤生长策略［J］.生命的化学,2017,37(05):726-732.
ZHANG MY,SUN YD,LUO Y.Pentose phosphate pathway reprogramming and tumorigenic strategy［J］.Chemistry of Life,2017,37(05):726-732.
［70］ HUANG B,SONG BL,XU C.Cholesterol metabolism in cancer:mechanisms and therapeutic opportunities［J］.Nat Metab,2020,2(2):132-141.
［71］ ZHANG J,LIU Q.Cholesterol metabolism and homeostasis in the brain［J］.Protein Cell,2015,6(4):254-264.
［72］ ZELCER N,HONG C,BOYADJIAN R,et al.LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor［J］.Science,2009,325(5936):100-104.